Resiquimod

• CAT Number: I001738
• CAS Number: 144875-48-9
• Molecular Formula: C17H22N4O2
• Molecular Weight: 314.40
• Purity: ≥95%
• Synonyms: 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
• Target: Toll-like Receptor (TLR)
• Solubility: DMSO: ≥ 40 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
• InChIKey: BXNMTOQRYBFHNZ-UHFFFAOYSA-N
• SMILES: CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N

Resiquimod(CAT: I001738) is a small molecule agonist of Toll-like receptor 7 (TLR7) and TLR8, which are proteins involved in the innate immune response. It is a synthetic derivative of the natural product imiquimod and is used as a topical medication for the treatment of various skin conditions, including actinic keratosis, superficial basal cell carcinoma, and genital warts caused by human papillomavirus (HPV). Resiquimod works by activating the immune system to produce cytokines and chemokines, which in turn stimulate immune cells to attack the abnormal cells causing the skin condition. It has also been studied as a potential adjuvant therapy for cancer immunotherapy, as it can stimulate the immune system to recognize and attack cancer cells.

Overview of Clinical Research

Resiquimod is a Toll-like receptor 7/8 agonist, which is in the phase II study in Malignant melanoma.